EQRX Fundamental Analysis - EQRX INC

Fundamental Rating

EQRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. EQRX has a great financial health rating, but its profitability evaluates not so good. EQRX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

EQRX had negative earnings in the past year.

In the past year EQRX has reported a negative cash flow from operations.

1.2 Ratios

Looking at the Return On Assets, with a value of -20.04%, EQRX belongs to the top of the industry, outperforming 81.92% of the companies in the same industry.

EQRX's Return On Equity of -21.05% is amongst the best of the industry. EQRX outperforms 85.07% of its industry peers.

		Industry Rank	Sector Rank
ROA	-20.04%
ROE	-21.05%
ROIC	N/A

ROA(3y)-22.45%

ROA(5y)N/A

ROE(3y)-23.54%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EQRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for EQRX has been increased compared to 1 year ago.

EQRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 11.47 indicates that EQRX is not in any danger for bankruptcy at the moment.

EQRX has a better Altman-Z score (11.47) than 91.54% of its industry peers.

There is no outstanding debt for EQRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	11.47

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

EQRX has a Current Ratio of 22.60. This indicates that EQRX is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of EQRX (22.60) is better than 96.02% of its industry peers.

EQRX has a Quick Ratio of 22.60. This indicates that EQRX is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 22.60, EQRX belongs to the best of the industry, outperforming 96.02% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	22.6
Quick Ratio	22.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for EQRX have decreased strongly by -62.64% in the last year.

EPS 1Y (TTM)-62.64%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%11.76%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

EQRX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -9.08% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-92.67%

EPS Next 2Y-37.78%

EPS Next 3Y-19.35%

EPS Next 5Y-9.08%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EQRX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EQRX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as EQRX's earnings are expected to decrease with -19.35% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-37.78%

EPS Next 3Y-19.35%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EQRX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EQRX INC

NASDAQ:EQRX (11/8/2023, 8:00:02 PM)

After market: 2.39 +0.05 (+2.14%)

2.34

-0.05 (-2.09%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-09 2023-11-09/amc

Earnings (Next)N/A N/A

Inst Owners3.06%

Inst Owner Change0%

Ins Owners0.52%

Ins Owner Change0%

Market Cap1.26B

Analysts42.86

Price Target2.14 (-8.55%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-12.13%

Min EPS beat(2)-15.79%

Max EPS beat(2)-8.46%

EPS beat(4)2

Avg EPS beat(4)16.22%

Min EPS beat(4)-15.79%

Max EPS beat(4)75.91%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-17.65%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-15.11%

EPS NY rev (1m)0%

EPS NY rev (3m)-15.71%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.01
P/tB	1.01
EV/EBITDA	N/A

EPS(TTM)-0.55

EYN/A

EPS(NY)-0.68

Fwd EYN/A

FCF(TTM)-0.62

FCFYN/A

OCF(TTM)-0.61

OCFYN/A

SpS0

BVpS2.32

TBVpS2.32

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-20.04%
ROE	-21.05%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-22.45%

ROA(5y)N/A

ROE(3y)-23.54%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	203.78%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	22.6
Quick Ratio	22.6
Altman-Z	11.47

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)346.9%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-62.64%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%11.76%

EPS Next Y-92.67%

EPS Next 2Y-37.78%

EPS Next 3Y-19.35%

EPS Next 5Y-9.08%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y1.88%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-11.34%

EBIT Next 3Y2.85%

EBIT Next 5Y0.08%

FCF growth 1Y-57.06%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-56.82%

OCF growth 3YN/A

OCF growth 5YN/A

EQRX INC (EQRX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens